Stockreport

Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium

Calithera Biosciences, Inc.  (CALA) 
Last calithera biosciences, inc. earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: calithera.com
PDF SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering [Read more]